GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003133427 | Thyroid | HT | positive regulation of protein-containing complex assembly | 27/1272 | 237/18723 | 5.82e-03 | 3.74e-02 | 27 |
GO:19021703 | Thyroid | HT | cellular response to reactive nitrogen species | 5/1272 | 18/18723 | 5.83e-03 | 3.74e-02 | 5 |
GO:015011710 | Thyroid | HT | positive regulation of cell-substrate junction organization | 7/1272 | 33/18723 | 5.88e-03 | 3.74e-02 | 7 |
GO:005159218 | Thyroid | HT | response to calcium ion | 19/1272 | 149/18723 | 5.92e-03 | 3.76e-02 | 19 |
GO:00702312 | Thyroid | HT | T cell apoptotic process | 9/1272 | 50/18723 | 5.98e-03 | 3.77e-02 | 9 |
GO:00513535 | Thyroid | HT | positive regulation of oxidoreductase activity | 10/1272 | 59/18723 | 6.00e-03 | 3.77e-02 | 10 |
GO:00028327 | Thyroid | HT | negative regulation of response to biotic stimulus | 15/1272 | 108/18723 | 6.28e-03 | 3.94e-02 | 15 |
GO:00435027 | Thyroid | HT | regulation of muscle adaptation | 14/1272 | 98/18723 | 6.35e-03 | 3.97e-02 | 14 |
GO:007030110 | Thyroid | HT | cellular response to hydrogen peroxide | 14/1272 | 98/18723 | 6.35e-03 | 3.97e-02 | 14 |
GO:004328025 | Thyroid | HT | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 17/1272 | 129/18723 | 6.45e-03 | 4.03e-02 | 17 |
GO:00508104 | Thyroid | HT | regulation of steroid biosynthetic process | 11/1272 | 69/18723 | 6.52e-03 | 4.06e-02 | 11 |
GO:190437724 | Thyroid | HT | positive regulation of protein localization to cell periphery | 11/1272 | 69/18723 | 6.52e-03 | 4.06e-02 | 11 |
GO:00461852 | Thyroid | HT | aldehyde catabolic process | 4/1272 | 12/18723 | 6.75e-03 | 4.16e-02 | 4 |
GO:19034059 | Thyroid | HT | protein localization to nuclear body | 4/1272 | 12/18723 | 6.75e-03 | 4.16e-02 | 4 |
GO:190359910 | Thyroid | HT | positive regulation of autophagy of mitochondrion | 4/1272 | 12/18723 | 6.75e-03 | 4.16e-02 | 4 |
GO:19048679 | Thyroid | HT | protein localization to Cajal body | 4/1272 | 12/18723 | 6.75e-03 | 4.16e-02 | 4 |
GO:003070520 | Thyroid | HT | cytoskeleton-dependent intracellular transport | 23/1272 | 195/18723 | 6.91e-03 | 4.21e-02 | 23 |
GO:005110026 | Thyroid | HT | negative regulation of binding | 20/1272 | 162/18723 | 6.91e-03 | 4.21e-02 | 20 |
GO:000616525 | Thyroid | HT | nucleoside diphosphate phosphorylation | 14/1272 | 99/18723 | 6.94e-03 | 4.22e-02 | 14 |
GO:000688816 | Thyroid | HT | endoplasmic reticulum to Golgi vesicle-mediated transport | 17/1272 | 130/18723 | 6.97e-03 | 4.22e-02 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |